Adjust cookies
If you click on "Accept all cookies", you agree to the storage of cookies on your device in order to improve the navigation on the website, to analyze the use of the website and to support our marketing activities.
Essential cookeis
- Session cookies
Performance cookies
Functional cookies
- Google Maps
- YouTube
- SocialShare Buttons
- Linkedin Insight
Targeting cookies
-Facebook Pixel

Hansa Biopharma AB

Bransch
Biotechnology & Pharmaceuticals
Stad
Lund
Grundat år
2007
           

Om organisationen

Hansa Biopharma is leveraging its proprietary enzyme technology platform to enable immunomodulatory treatments for transplants, rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy and cancer. The Company’s lead product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation and acute autoimmune indications. The European Commission has conditionally approved Idefirix (imlifidase) for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Hansa’s research and development program is also advancing the Company’s enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in other European countries and in the U.S.
Read more
©2021 Great Place to Work® Institute Inc. All Rights Reserved.
made with by CIC